BRAXIA SCIENTIFIC ANNOUNCES PARTICIPATION AT CANACCORD GENUITY 2021 ANNUAL GROWTH CONFERENCE AUGUST 10-12
See full press release TORONTO, ONTARIO Aug. 6, 2021 – Braxia Scientific Corp. (“Braxia”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 496), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disorders, is pleased to announce its participation at the upcoming Canaccord Genuity Annual Growth Conference. The conference will be held virtually on August 10-12, 2021. Braxia Scientific CEO Dr. Roger McIntyre will deliver a presentation on the company’s initiatives related to developing novel therapeutics and delivery systems for treating depression and other brain-based disorders, as well as its administration of patient care in its network of clinics.
CANACCORD GENUITY 2021 ANNUAL GROWTH CONFERENCE
BRAXIA SCIENTIFIC ANNOUNCES PARTICIPATION AT CANACCORD GENUITY 2021 ANNUAL GROWTH CONFERENCE AUGUST 10-12 TORONTO, ONTARIO Aug. 6, 2021 – Braxia Scientific Corp. (“Braxia”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 496), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disorders, is pleased to announce its participation at the upcoming Canaccord Genuity Annual Growth Conference. The conference will be held virtually on August 10-12, 2021. Braxia Scientific CEO Dr. Roger McIntyre will deliver a presentation on the company’s initiatives related to developing novel therapeutics and delivery systems for treating depression and other brain-based disorders, as well as its administration of patient care in its network of clinics. Presentation Details: Date: Tuesday, August 10, 2021 Time: 11:30 a.m. ET Event Registration: https://bit.ly/3josIt3 For additional information on the conference, please CLICK HERE. About Braxia Scientific Corp. Braxia Scientific is a...
CORPORATE UPDATE AND REPORTING
BRAXIA SCIENTIFIC PROVIDES CORPORATE UPDATE AND REPORTS FISCAL FOURTH QUARTER AND FULL-YEAR 2021 FINANCIAL RESULTS TORONTO, ONTARIO July 30, 2021 – Braxia Scientific Corp. (“Braxia”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 496), today announced the filing of its fiscal fourth-quarter and year-end results for the three- and 12-month periods ending March 31, 2021. Complete financial statements along with related management discussion and analysis can be found in the System for Electronic Document Analysis and Retrieval (SEDAR), the electronic filing system for the disclosure documents of issuers across Canada at www.SEDAR.com. Through its global leading researchers and experienced implementation team, Braxia Scientific has established its presence in the mental health industry. Braxia Scientific successfully expanded its network of multidisciplinary clinics to four in 2021, with one of very few private clinics approved in Canada to provide innovative intravenous (IV) Ketamine treatments to...
EXPERIMENTAL MEDICINE IN PSYCHIATRY
BRAXIA SCIENTIFIC TO DISCUSS PSYCHIATRIC TREATMENT DISCOVERY AND DEVELOPMENT WITH OXFORD UNIVERSITY RESEARCHERS AT AIMDAY EXPERIMENTAL MEDICINE IN PSYCHIATRY ON JULY 7, 2021 TORONTO, ONTARIO July 7, 2021 – Braxia Scientific Corp. (“Braxia”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 496), a medical research and development company along with clinics providing innovative ketamine treatments for persons with depression and related disorders, is pleased to announce its participation at the upcoming Academic Industry Meeting Day (AIMday) on “Experimental Medicine in Psychiatry,” hosted by Oxford University on Wednesday, July 7, 2021. Braxia CEO Dr. Roger McIntyre will engage with Oxford scientists on the question of “How can we advance treatment discovery and development in psychiatry targeting cognition?” They will describe how research will be conducted with ketamine and psychedelics that integrates machine-learning, proof-of-mechanism research and implementation science which will be critical for the...
BRAXIA SCIENTIFIC ANNOUNCES PARTICIPATION AT PSYCH INVESTOR SUMMIT ON JULY 7, 2021
See full press release TORONTO, ONTARIO July 6, 2021 – Braxia Scientific Corp. (“Braxia”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 496), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disorders, is pleased to announce its participation at the upcoming PSYCH Investor Summit: Research & Development. The conference will be held virtually on July 7, 2021. Braxia CEO Dr. Roger McIntyre will deliver a presentation discussing the recently announced funding by the Canadian Institutes Of Health Research (CIHR), of the Government of Canada, to support the first of its kind Ketamine clinical trial for Bipolar Depression. Additionally, Dr. McIntyre will discuss Braxia’s initiatives related to developing innovative therapeutics and delivery systems, while also administering patient care in its growing network of clinics. The presentation will be followed by a Q&A. Dr. McIntyre...
PSYCH INVESTOR SUMMIT
BRAXIA SCIENTIFIC ANNOUNCES PARTICIPATION AT PSYCH INVESTOR SUMMIT ON JULY 7, 2021 TORONTO, ONTARIO July 6, 2021 – Braxia Scientific Corp. (“Braxia”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 496), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disorders, is pleased to announce its participation at the upcoming PSYCH Investor Summit: Research & Development. The conference will be held virtually on July 7, 2021. Braxia CEO Dr. Roger McIntyre will deliver a presentation discussing the recently announced funding by the Canadian Institutes Of Health Research (CIHR), of the Government of Canada, to support the first of its kind Ketamine clinical trial for Bipolar Depression. Additionally, Dr. McIntyre will discuss Braxia’s initiatives related to developing innovative therapeutics and delivery systems, while also administering patient care in its growing network of clinics. The presentation will...
Quebec Curfew May Increase Feelings of Loneliness: Psychiatrist
TORONTO -- Sparked by an explosion of COVID-19 cases, Quebec’s month-long curfew could increase people’s feelings of loneliness, one expert warned, urging people to maintain personal connections and physical activity. “People are getting fed up with the uncertainty.” Roger McIntyre, a psychiatry and pharmacology professor from the University of Toronto, told CTV News Channel on Sunday. McIntyre understands how maddening it must be for Quebecers to contend with yet another measure when they are already facing economic strife under COVID-19 public health restrictions.
‘Loneliness pandemic’: Work from home during COVID-19 takes mental toll on Canadians
“Working from home for many people in our society is a risk for further alienation and feeling very lonely and distant,” said Dr. Roger McIntyre”
VeraCity: The Psychedelic Frontier
VeraCity: The Psychedelic Frontier aired January 25 on Citytv. Dr. McIntyre speaks about research and treatments.
Challenges of parenting during the pandemic
Dr. Roger McIntyre on the challenges of parenting during COVID
A phone call may be all it takes to ease pandemic loneliness: study
TORONTO -- Give your friends and family a call, it may just ease the pandemic loneliness, depression and anxiety that are taking hold. A study published in the peer-reviewed journal JAMA Psychiatry suggests that phone calls can help people who are left feeling alone and isolated during the pandemic, no training required. This isn’t overly surprising, for humans have a basic need to connect with others, said Roger McIntyre, a psychiatry and pharmacology professor at the University of Toronto. “It speaks to the fact that as people, as human beings, we need to have contact. That is an undeniable fact. It’s in our DNA, years of evolution. We’re social organisms, we need contact,” McIntyre told CTVNews.ca in a phone interview on Wednesday. The study aimed to quickly address the issue of loneliness during the pandemic and focused on socially isolated adults who...